GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.

GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals.
复制标题

DOI:
10.1016/j.nbd.2008.10.007
复制
发表时间:
2009-02
影响因子:
6.1
通讯作者:
Frautschy SA
Frautschy SA
中科院分区:
医学1区
文献类型:
--
作者:
Hu S;Begum AN;Jones MR;Oh MS;Beech WK;Beech BH;Yang F;Chen P;Ubeda OJ;Kim PC;Davies P;Ma Q;Cole GM;Frautschy SA

文献摘要

参考文献

被引文献

相似文献

糖原合成酶激酶-3(GSK 3)的失调与阿尔茨海默病(AD)的发病机制和Aβ诱导的神经毒性有关,因此我们将其作为脑室内Aβ输注模型的治疗靶点进行了研究。输注特异性GSK 3抑制剂SB 216763(SB)使下游靶点磷酸糖原合酶降低39%,并使糖原水平增加44%,表明有效抑制酶活性。与溶剂相比,Aβ增加了GSK 3活性,并与ptau、caspase-3、tau激酶磷酸-c-jun N-末端激酶(pJNK)水平升高、神经元DNA片段化和神经胶质增生相关。SB的共输注纠正了对Aβ输注的所有反应,除了Morris水迷宫中神经胶质增生和行为缺陷的诱导。然而,SB单独与神经退行性标志物和行为缺陷的诱导相关。这些数据支持了在AD发病机制中GSK 3过度活化的作用,但强调了开发不抑制组成性活性的抑制剂的重要性。
The dysregulation of glycogen synthase kinase-3 (GSK3) has been implicated in Alzheimer disease (AD) pathogenesis and in Aβ-induced neurotoxicity, leading us to investigate it as a therapeutic target in an intracerebroventricular Aβ infusion model. Infusion of a specific GSK3 inhibitor SB216763 (SB) reduced a downstream target, phospho-glycogen synthase 39%, and increased glycogen levels 44%, suggesting effective inhibition of enzyme activity. Compared to vehicle, Aβ increased GSK3 activity, and was associated with elevations in levels of ptau, caspase-3, the tau kinase phospho-c-jun N-terminal kinase (pJNK), neuronal DNA fragmentation, and gliosis. Co-infusion of SB corrected all responses to Aβ infusion except the induction of gliosis and behavioral deficits in the Morris water maze. Nevertheless, SB alone was associated with induction of neurodegenerative markers and behavioral deficits. These data support a role for GSK3 hyperactivation in AD pathogenesis, but emphasize the importance of developing inhibitors that do not suppress constitutive activity.
DOI: 10.1074/jbc.274.30.21395
发表时间: 1999-07-23
影响因子: 4.8
作者:
Hartigan, JA;Johnson, GVW
通讯作者: Johnson, GVW
DOI: 10.4049/jimmunol.181.1.338
发表时间: 2008-07-01
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者:
De Sarno P;Axtell RC;Raman C;Roth KA;Alessi DR;Jope RS
通讯作者: Jope RS
DOI: 10.1074/jbc.m204861200
发表时间: 2002-09-13
影响因子: 4.8
作者:
Carmichael, J;Sugars, KL;Rubinsztein, DC
通讯作者: Rubinsztein, DC
DOI: 10.1007/bf02815006
发表时间: 1996-10-01
期刊: MOLECULAR AND CHEMICAL NEUROPATHOLOGY
影响因子: --
作者:
Baum, L;Hansen, L;Saitoh, T
通讯作者: Saitoh, T
DOI: 10.1016/j.bbrc.2005.08.130
发表时间: 2005-10-21
影响因子: 3.1
作者:
Akiyama, H;Shin, RW;Uchida, T
通讯作者: Uchida, T